Hauben M - Search Results

1

A mathematical framework to quantify the masking effect associated with the confidence intervals of measures of disproportionality.

Maignen F, Hauben M, Dogné JM. Maignen F, et al. Among authors: hauben m. Ther Adv Drug Saf. 2017 Jul;8(7):231-244. doi: 10.1177/2042098617704143. Epub 2017 May 5. Ther Adv Drug Saf. 2017. PMID: 28845231 Free PMC article.

2

Detection of spironolactone-associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES).

Hauben M, Reich L, Gerrits CM, Madigan D. Hauben M, et al. Drug Saf. 2007;30(12):1143-9. doi: 10.2165/00002018-200730120-00006. Drug Saf. 2007. PMID: 18035866

3

Modelling the time to onset of adverse reactions with parametric survival distributions: a potential approach to signal detection and evaluation.

Maignen F, Hauben M, Tsintis P. Maignen F, et al. Among authors: hauben m. Drug Saf. 2010 May 1;33(5):417-34. doi: 10.2165/11532850-000000000-00000. Drug Saf. 2010. PMID: 20397741

4

Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases.

Maignen F, Hauben M, Hung E, Van Holle L, Dogne JM. Maignen F, et al. Among authors: hauben m. Pharmacoepidemiol Drug Saf. 2014 Feb;23(2):195-207. doi: 10.1002/pds.3529. Epub 2013 Nov 15. Pharmacoepidemiol Drug Saf. 2014. PMID: 24243665

5

A conceptual approach to the masking effect of measures of disproportionality.

Maignen F, Hauben M, Hung E, Holle LV, Dogne JM. Maignen F, et al. Among authors: hauben m. Pharmacoepidemiol Drug Saf. 2014 Feb;23(2):208-17. doi: 10.1002/pds.3530. Epub 2013 Nov 15. Pharmacoepidemiol Drug Saf. 2014. PMID: 24243699

6

Safety of Perflutren Ultrasound Contrast Agents: A Disproportionality Analysis of the US FAERS Database.

Hauben M, Hung EY, Hanretta KC, Bangalore S, Snow V. Hauben M, et al. Drug Saf. 2015 Nov;38(11):1127-39. doi: 10.1007/s40264-015-0332-6. Drug Saf. 2015. PMID: 26242615

7

Revisiting the reported signal of acute pancreatitis with rasburicase: an object lesson in pharmacovigilance.

Hauben M, Hung EY. Hauben M, et al. Ther Adv Drug Saf. 2016 Jun;7(3):94-101. doi: 10.1177/2042098616647955. Epub 2016 May 23. Ther Adv Drug Saf. 2016. PMID: 27298720 Free PMC article.

8

Does serious consequential masking exist? An update.

Hauben M, Maignen F. Hauben M, et al. Pharmacoepidemiol Drug Saf. 2017 Jun;26(6):727-729. doi: 10.1002/pds.4209. Pharmacoepidemiol Drug Saf. 2017. PMID: 28573827 No abstract available.

9

The impact of database restriction on pharmacovigilance signal detection of selected cancer therapies.

Hauben M, Hung E, Wood J, Soitkar A, Reshef D. Hauben M, et al. Ther Adv Drug Saf. 2017 May;8(5):145-156. doi: 10.1177/2042098616685010. Epub 2017 Feb 1. Ther Adv Drug Saf. 2017. PMID: 28588760 Free PMC article.

10

Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database.

Capogrosso Sansone A, Convertino I, Galiulo MT, Salvadori S, Pieroni S, Knezevic T, Mantarro S, Marino A, Hauben M, Blandizzi C, Tuccori M. Capogrosso Sansone A, et al. Among authors: hauben m. Drug Saf. 2017 Oct;40(10):895-909. doi: 10.1007/s40264-017-0564-8. Drug Saf. 2017. PMID: 28681266

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

127 results

Search Page

Filters